First day of trading in Ectin Research
Today is the first day of trading in Ectin Research, a pharmaceutical company that specializes in research and development of drug candidates, primarily for bladder cancer.
Ectin Research was founded in 2013 and is active in biotechnology. The company specializes in the research and development of drug candidates. The research is focused on developing drugs that aim to eliminate cancerous tumors in patients, with the greatest focus on the treatment of bladder cancer. In addition, the company intends to develop drugs for the treatment of breast, colorectal, and prostate cancer cells.
“We are very happy for the interest in Ectin that the issue of shares has shown. The IPO process has made Ectin visible on the market and given new shareholders the possibility to join and share our ambition to establish MFA-370 as the first oral treatment for metastatic urothelial bladder cancer with few and tolerable potential side effects. The capital makes it now financially possible for us to initiate the planned phase I/II study during H2 2021,“ says, CEO, Anna Sjöblom-Hallén.
“Today, trading begins in Ectin Research, active with their treatment therapy for bladder cancer - a warm welcome to Spotlight!”, says Carl-Henrik Nordberg, Head of Listing, Spotlight.
Press contact
Anders Eriksson, Head of Marketplace Spotlight
+46 79 006 65 66, ae@spotlightstockmarket.com
ABOUT SPOTLIGHT
Spotlight is the marketplace where investors and growth companies meet. At Spotlight, it is easier and safer for companies to be listed. We offer an overall solution that increases the visibility of our companies through unique media collaborations. Investors get through Spotlight the opportunity to become shareholders in approximately 160 growth companies from different businesses and countries, among those are Freetrailer, Bahnhof, and Synthetic MR.
